Amgen's latest marketcap:
As of 07/30/2025, Amgen's market capitalization has reached $163.23 B. According to our data, Amgen is the 101th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 163.23 B |
| Revenue (ttm) | 34.13 B |
| Net Income (ttm) | 5.93 B |
| Shares Out | 537.71 M |
| EPS (ttm) | 10.94 |
| Forward PE | 14.63 |
| Ex-Dividend Date | 05/16/2025 |
| Earnings Date | 08/05/2025 |
Amgen's yearly market capitalization.
| Date | Market Cap($) | Change (%) | Global Rank |
|---|---|---|---|
| 07/30/2025 | $163.23 B | 15.63% | 101 |
| 12/31/2024 | $140.1 B | -9.11% | 104 |
| 12/29/2023 | $154.14 B | 9.99% | 79 |
| 12/30/2022 | $140.14 B | 10.59% | 79 |
| 12/31/2021 | $126.72 B | -5.33% | 114 |
| 12/31/2020 | $133.85 B | -6.55% | 91 |
| 12/31/2019 | $143.24 B | 15.47% | 61 |
| 12/31/2018 | $124.05 B | -1.73% | 55 |
| 12/29/2017 | $126.24 B | 16.06% | 62 |
| 12/30/2016 | $108.77 B | -11.17% | 54 |
Company Profile
About Amgen Inc.
Amgen Inc. is a global biotechnology company focused on discovering, developing, manufacturing, and delivering innovative human therapeutics. Headquartered in Thousand Oaks, California, the company was founded in 1980 and serves healthcare providers worldwide.
Key Products
Amgen’s portfolio includes a range of leading therapies for serious illnesses:
- Enbrel: Treats rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis.
- Otezla: Addresses plaque psoriasis, psoriatic arthritis, and Behçet’s disease-related oral ulcers.
- Prolia & EVENITY: Osteoporosis treatments for postmenopausal women and men.
- Repatha: Reduces risks of myocardial infarction, stroke, and coronary revascularization.
- KYPROLIS: For relapsed or refractory multiple myeloma.
- BLINCYTO: Treats acute lymphoblastic leukemia.
- TEPEZZA: Targets thyroid eye disease.
- KRYSTEXXA: Addresses chronic refractory gout.
- Other notable products: Neulasta, MVASI, TEZSPIRE, Aimovig, LUMAKRAS, and more.
Market & Distribution
Amgen serves healthcare providers, including physicians, clinics, dialysis centers, hospitals, and pharmacies. Its products are distributed through pharmaceutical wholesalers and direct-to-consumer channels.
Strategic Collaborations
The company partners with leading organizations to expand its therapeutic reach:
- AstraZeneca: Development and commercialization of TEZSPIRE.
- Novartis: Collaboration on Aimovig.
- UCB: Joint efforts for EVENITY.
- Kyowa Kirin: Rocatinlimab development.
- BeiGene: Oncology product expansion.
Frequently Asked Questions
-
What is Amgen's (AMGN) current market cap?As of 07/30/2025, Amgen (including the parent company, if applicable) has an estimated market capitalization of $163.23 B USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Amgen (AMGN) rank globally by market cap?Amgen global market capitalization ranking is approximately 101 as of 07/30/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.